# US 2012/0232065 A1 · Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232065 A1
- Document ID: US20120232065A1
- Status: Published application
- Kind: A1
- Application number: 13/413,977
- Filed: 2012-03-07
- Published: 2012-09-13
- Earliest claimed: 2011-03-08
- Assignees: Egis Gyogyszergyar Nyrt; Les Laboratoires Servier
- Inventors: István LING; József BARKÓCZY; Ferenc ANTONI; István GACSÁLYI; György LÉVAY; Michael SPEDDING; László HÁRSING
- Web page: https://patentgrep.com/patent/US20120232065A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I): wherein: R1 represents a hydrogen atom or an alkyl group; R2 represents an alkyl group; R3 represents an aryl or heteroaryl group. Medicinal products containing the same which are useful in the treatment or prevention of psychiatric and neurological disorders characterised by cognitive deficits.

## Claims

### Claim 1

A compound selected from those of formula (I):
wherein:
R1 represents a hydrogen atom or a linear or branched (C1-C4)alkyl group;
R2 represents a linear or branched (C1-C4)alkyl group;
R3 represents an aryl or heteroaryl group;
and positional isomers, enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid, and solvates, complexes and adducts thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 represents a hydrogen atom.

### Claim 3 (depends on 1)

The compounds of claim 1, wherein R2 represents a methyl group.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R3 represents a heteroaryl group.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R3 represents a bicyclic aromatic group having from 1 to 3 identical or different hetero atoms selected from nitrogen, oxygen and sulphur, optionally substituted by one or more identical or different groups selected from a halogen atom; a linear or branched (C1-C6)alkyl group which is unsubstituted or substituted by one or more halogen atoms; a linear or branched (C1-C6)alkoxy group; a linear or branched (C1-C6)alkylcarbonyl group; a carboxy group; a linear or branched (C1-C6)alkoxycarbonyl group; a hydroxy group; a cyano group; a nitro group; an aminocarbonyl group which is unsubstituted or substituted by one or more linear or branched (C1-C6)alkyl groups; and an amino group which is unsubstituted or substituted by one or two linear or branched (C1-C6)alkyl groups.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R3 represents a benzothienyl or quinolyl group, optionally substituted by one or more identical or different groups selected from a halogen atom and a linear or branched (C1-C4)alkyl group which is unsubstituted or substituted by one or more halogen atoms.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R3 represents a 1-benzothienyl group, optionally substituted by one or more identical or different groups selected from a halogen atom and a linear or branched (C1-C4)alkyl group which is unsubstituted or substituted by one or more halogen atoms.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R3 represents a 1-benzothien-2-yl group, optionally substituted by one or more identical or different groups selected from a halogen atom and a linear or branched (C1-C4)alkyl group which is unsubstituted or substituted by one or more halogen atoms.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R3 represents a 1-benzothien-2-yl group, optionally substituted by one or more identical or different groups selected from a fluorine atom, a chlorine atom, a trifluoromethyl group and a methyl group.

### Claim 10 (depends on 1)

The compound of claim 1, which is selected from:
5-(4-fluoro-1-benzothien-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]-benzodiazepin-2-one;
8-methyl-5-(6-quinolyl)-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one;
5-(1-benzothien-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one;
5-(5-chloro-1-benzothien-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]-benzodiazepin-2-one;
5-[3-chloro-4-(trifluoromethyl)-1-benzothien-2-yl]-8-methyl-1,9-dihydro-2H-[1,3]-oxazolo[4,5-h][2,3]benzodiazepin-2-one;
8-methyl-5-[4-(trifluoromethyl)-1-benzothien-2-yl]-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one;
5-(6-fluoro-1-benzothien-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]-benzodiazepin-2-one;
5-(7-fluoro-1-benzothien-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]-benzodiazepin-2-one.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising as active ingredient a compound of claim 1 in combination with one or more inert, non-toxic, pharmaceutically acceptable carriers.

### Claim 12 (depends on 1)

A method for treating or preventing a condition selected from schizophrenia, unipolar depression, Alzheimer's disease, vascular dementia, autism spectrum disorders, Down's syndrome, fragile X syndrome, Parkinson's disease, Huntington's disease, generalised anxiety, panic disorder with or without agoraphobia, obsessive-compulsive disorders, post-traumatic stress disorders, bipolar disorders, sequelae of a cerebral vascular accident and sequelae of brain, spine or medullary trauma in a subject in need thereof, comprising administration of an effective amount of a compound of claim 1.
